reports
- Jacob Mekhael
Zealand Pharma Initiation: Shifting pounds into profit
Zealand is a Danish biotech with a broad pipeline in obesity and rare disease. Petrelintide (amylin analog) could become a monotherapy challenger to GLP-1 drugs based on its efficacy and tolerability in phase 1b, and phase 2b results in 2026 could set petrelintide up to capture a significant share of the $140b obesity market as the go to option for GLP-1 intolerant patients, weight loss maintenance and beyond. In addition, survodutide (GLP-1/glucagon analog) is already out-licenced to BI with on...
Zealand Pharma to participate in the Jefferies London Healthcare Confe...
Zealand Pharma to participate in the Jefferies London Healthcare Conference Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies London Healthcare Conference at 9:30 a.m. GMT (10:30 a.m. CET) on Thursday, November 21, 2024. A liv...
Zealand Pharma AS: 1 director
A director at Zealand Pharma AS sold 1,500 shares at 849.000DKK and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Zealand Pharma Announces Financial Results for the First Nine Months o...
Zealand Pharma Announces Financial Results for the First Nine Months of 2024 Company announcement – No. 49 / 2024 Zealand Pharma Announces Financial Results for the First Nine Months of 2024 Continued strong progress across obesity pipeline with proprietary assets ready for Phase 2 backed by a solid financial position. Presented extremely encouraging weight loss and tolerability data with long-acting amylin analog petrelintide from MAD Part 2 (16-week trial) at ObesityWeek 2024Announced positive topline results with GLP-1R/GLP-2R dual agonist dapiglutide from Part 1 of Phase 1b trial ...
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to pr...
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 7, 2024, at 2:00 pm CET (8:00 am ET) following the announcement...
- Dominic Rose
- Naresh Chouhan
Obesity Thematic - A Deep-Dive into Amylin
In the coming days at Obesity Week, we will see multiple datasets from amylin assets that could help to further support our belief that amylin combinations could become a material MOA in the Obesity market. Ahead of the Cagrisema P3 readout, we dig deep into the potential for amylin and show: 1) It has a superior tolerability profile, 2) Could preserve lean muscle mass and 3) Could be neuroprotective. We analyse the majority of the clinical data available on these drugs & show that the full prom...
Zealand Pharma provides U.S. regulatory update on dasiglucagon in cong...
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for dasiglucagon in CHI for up to three weeks of dosing due to the timing of a third-party manufacturing facility reinspectionThe reinspection of the facility was completed in August/September 2024 for which a new inspection classification is pendingZealand remains committed to working wit...
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthroug...
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide Company announcement – No. 47 / 2024 Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II s...
Total number of shares and voting rights in Zealand Pharma A/S on Sept...
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 Company announcement – No. 46 / 2024 Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 Copenhagen, Denmark, September 30, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calen...
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Con...
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th Press Release – No. 9 / 2024 Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th Copenhagen, Denmark, September 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Medical Officer, David Kendall, MD, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference at 9:10 a.m. ET (3:10 p.m. CET) on W...
Zealand Pharma Increases its Share Capital as a Consequence of Exercis...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Company announcement – No. 45 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 12, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 10,110 divided into 10,110 new shares with a nominal value of DKK 1 each. The inc...
Zealand Pharma announces positive topline results from 13-week Phase 1...
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly dosesDapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events ...
Zealand Pharma Increases its Share Capital as a Consequence of Exercis...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Company announcement – No. 41 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, August 22, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 13,000 divided into 13,000 new shares with a nominal value of DKK 1 each. Th...
Zealand Pharma major shareholder announcement: Bank of America Corpora...
Zealand Pharma major shareholder announcement: Bank of America Corporation Company announcement – No. 40 / 2024 Zealand Pharma major shareholder announcement: Bank of America Corporation Copenhagen, Denmark, 16 August 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports prior receipt on 19 March 2024 and 5 April 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder...
Zealand Pharma Announces Financial Results for the First Half of 2024
Zealand Pharma Announces Financial Results for the First Half of 2024 Company announcement - No. 39 / 2024 Zealand Pharma Announces Financial Results for the First Half of 2024 Very strong progress across R&D pipeline followed by substantial capital raise enabling further investments to accelerate the development programs for wholly owned obesity assets. Extremely encouraging weight loss and tolerability data announced with long-acting amylin analog petrelintide from MAD Part 2 (16-week trial)Impressive data from Boehringer Ingelheim’s Phase 2 clinical trial with survodutide in MASH...
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to pre...
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 15, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of...
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer Press release – 7 / 2024 Zealand Pharma Appoints Eric Cox as Chief Commercial Officer Copenhagen, Denmark, 29 July 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Eric Cox as Zealand’s Chief Commercial Officer starting August 5, 2024. Eric will join the executive team to lead Zealand’s commercial strategy and assume responsibility for business development. ...
Zealand Pharma major shareholder announcement: Van Herk Investments
Zealand Pharma major shareholder announcement: Van Herk Investments Company announcement – No. 38 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 28 June 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 28 June 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As from 28 June 2024 ...
Total number of shares and voting rights in Zealand Pharma at June 28,...
Total number of shares and voting rights in Zealand Pharma at June 28, 2024 Company announcement – No. 37 / 2024 Total number of shares and voting rights in Zealand Pharma at June 28, 2024 Copenhagen, Denmark, June 28, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during wh...
Zealand Pharma completes registration of capital increase
Zealand Pharma completes registration of capital increase Company announcement – No. 36 / 2024 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SECURITIES IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.